15 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2026 | $1.3B | $97308 | 59.0% | 11.7% | $260M | $1.2B | $245M |
| 2025 | $1.4B | $167679 | 55.0% | 16.3% | $142M | $1.2B | $307M |
| 2024 | $1.3B | $118M | 52.8% | 12.6% | $144M | $808M | $179M |
| 2023 | $1.2B | $115M | 52.6% | 13.4% | $82M | $766M | $284M |
| 2022 | $993M | $43M | 50.9% | 8.1% | $76M | $774M | $259M |
| 2021 | — | $79M | — | — | $72M | $708M | $192M |
| 2020 | — | $77M | — | — | $109M | $382M | $137M |
| 2019 | — | $55M | — | — | $40M | $350M | $169M |
| 2018 | — | $46M | — | — | $146M | $254M | $180M |
| 2017 | — | -$26M | — | — | $84M | $316M | $140M |
| 2016 | — | -$56M | — | — | $19M | $408M | $115M |
| 2015 | — | $17M | — | — | $5M | $430M | $161M |
| 2014 | — | $35M | — | — | $66M | $440M | $192M |
| 2013 | — | $39M | — | — | $23M | $486M | $179M |
| 2012 | — | $67M | — | — | $62M | $4M | $229M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $346M | -$20M | 57.2% | -6.6% | $53M | $1.2B | $245M |
| Dec '25 | $339M | $45M | 59.7% | 19.9% | $87M | $1.2B | $363M |
| Sep '25 | $327M | $39M | 59.5% | 17.9% | $106M | $1.2B | $296M |
| Jun '25 | $321M | $34M | 59.8% | 16.8% | $14M | $1.2B | $293M |
| Mar '25 | $331M | $58M | 58.4% | 21.6% | $101M | $1.2B | $307M |
| Dec '24 | $349M | $37M | 55.5% | 16.9% | $35M | $1.2B | $321M |
| Sep '24 | $346M | $34M | 54.2% | 15.0% | $39M | $1.2B | $299M |
| Jun '24 | $336M | $38M | 52.0% | 11.8% | -$33M | $1.2B | $344M |
| Mar '24 | $343M | $20M | 51.2% | 8.7% | $57M | $808M | $179M |
| Dec '23 | $336M | $31M | 52.9% | 13.7% | -$15M | $871M | $194M |
| Sep '23 | $318M | $25M | 53.6% | 11.1% | $90M | $762M | $351M |
| Jul '23 | $311M | $41M | 53.7% | 17.2% | $11M | $765M | $286M |
| Apr '23 | $304M | $29M | 51.3% | 11.6% | $68M | $766M | $284M |
| Dec '22 | $305M | $33M | 52.0% | 14.2% | $48M | $767M | $224M |
| Oct '22 | $297M | $33M | 53.1% | 15.7% | $51M | $818M | $241M |
| Jul '22 | $261M | $20M | 54.4% | 11.8% | -$3M | $770M | $215M |
| Apr '22 | — | $10M | — | — | $33M | $774M | $259M |
| Jan '22 | $260M | $23M | 53.3% | 13.7% | $36M | $777M | $237M |
| Oct '21 | $240M | $15M | 51.1% | 10.2% | $23M | $781M | $192M |
| Jul '21 | $229M | -$4M | 47.3% | 0.6% | -$16M | $784M | $173M |
How the market has priced HAE against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Haemonetics Corp's revenue has grown 7.7% per year, and net income declined 73.8% per year. These are computed facts, not advice.
As of FY2026, Haemonetics Corp reported $1.2B of total debt against $245M of cash.
In FY2026, gross margin was 59.0%, operating margin 11.7%, and net margin 0.0%.
As of Jun '26, Haemonetics Corp traded at a price-to-earnings ratio of about 36255.7× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.